BLFS — BioLife Solutions Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for BioLife Solutions, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-8.91	-140	-66.4	-20.2	-4.59
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	13.8	135	40.2	19.8	28.9
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-2.26	-14.9	1.47	0.227	-8.91
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	-4.59	-8.49	-12.5	8.43	20.1
Capital Expenditures	-14.8	-13.9	-11.2	-5.59	-20.6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1.56	-44.2	29.1	63.9	-51
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	-13.2	-58.1	17.8	58.3	-71.5
Financing Cash Flow Items	-1.3	-1.84	0.338	-0.377	-0.942
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-2.78	16.3	10.6	-6.78	-10.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-20.6	-50.4	16	59.9	-62.3